FDLI’s first Food and Drug Policy Forum for 2016, guest-edited by Brenda Seidman, offers multistakeholder perspectives on FDA’s recent Warning Letters concerning bulk pure pow...read more
In “The Story and the Rest of the Story,” issue #10 of the Food and Drug Policy Forum’s 2015 edition, Peter Pitts and Robert Goldberg of the Center for Medicine in the Public Inte...read more
FDLI’s Food and Drug Policy Forum #9 (2015), “What Does the Future Hold for Patient-Focused Drug Development?” analyzes the emergence of PFDD as a critical componen...read more
Food and Drug Policy Forum Volume 5, issue 8, 2015, September, 2015.
How regulatory updates allowing for more modern test methods, pragmatic validation of preclinical test methods, and fda guidan...read more
Food and Drug Policy Forum Volume 5, issue 7, 2015, August 19, 2015.
Peter Huber and Paul Howard of the Manhattan Institute for Policy Research analyze the disjuncture between biomarker scienc...read more
Volume 5 Issue 2 of the FDLI Policy Forum – Regulating Laboratory Developed Tests (LDTs)
Michelle Bayefsky,National Institutes of Health Department of Bioethics,
Benjamin E. Berkman, Nation...read more
Federal Marijuana Regulation: Why is Flexibility Critical in the Dawn of Legalization?
Andrew Ittleman, Esq., Partner, Fuerst Ittleman David & Joseph, PL
Jessika Tuazon, Esq., Associate, Fuerst...read more
Issue 10 of the FDLI Food and Drug Policy Forum, entitled “Post-Market Drug Regulation in the Age of Big Data: What Path to the Promised Land?” focuses on how to best maximize the value...read more
In this Policy Forum, Authors Ryan Abbott and Ian Ayres explore the issue of extrapolation arising in the regulation of medicine. The authors note this extrapolation problem can arise when physicia...read more
Policy Forum – Oral Contraceptives to Over-the-Counter Status
This issue of Policy Forum (Volume 4, Number 3, March 12, 2014) – Should Oral Contraceptives Be Available Over the Counter?...read more